Form 4: UTHR Executive Sells Shares Under 10b5-1 Plan

United Therapeutics EVP & General Counsel Paul A. Mahon exercised stock options and sold 11,000 shares as part of a pre-arranged 10b5-1 trading plan.

Summary

• Paul A. Mahon, EVP & General Counsel of United Therapeutics Corp (UTHR), engaged in transactions on October 2, 2025.
• Mahon exercised 11,000 stock options at an exercise price of $135.42 per share.
• Concurrently, he sold 11,000 shares of common stock in multiple trades at weighted average prices ranging from $433.7234 to $440.1604.
• These transactions were executed pursuant to a pre-arranged Rule 10b5-1 trading plan established on December 24, 2024.
• Following these transactions, Mahon directly owns 36,781 shares of common stock and 44,000 derivative stock options.

Sentiment

Score: 5

Explanation: Neutral. While the executive profited significantly, the sale itself is a reduction in direct equity. However, it was pre-planned under a 10b5-1, mitigating negative interpretations. It doesn't reflect new positive or negative company performance.

Positives

• The executive realized a significant profit by exercising options at $135.42 and selling shares at prices over $433, indicating a substantial increase in share value since the options were granted.
• The transaction was conducted under a pre-arranged 10b5-1 plan, which suggests a planned liquidity event rather than a reaction to new, non-public information.

Negatives

• Insider selling, even if pre-planned, can sometimes be perceived negatively by the market as it reduces the executive's direct equity stake.

Risks

• No specific company operational risks are detailed in this Form 4 filing. The primary risk is potential negative market perception from insider selling, although mitigated by the 10b5-1 plan.

Future Outlook

NA

Management Comments

• This is an exercise of stock options and sale of the resulting shares pursuant to a pre-arranged 10b5-1 plan entered into by the reporting person on December 24, 2024.

Industry Context

This Form 4 filing is a routine disclosure of an insider transaction and does not provide information relevant to broader industry trends or competitive analysis for the biotechnology or pharmaceutical sector.

Stakeholder Impact

• Shareholders: May observe a slight negative sentiment due to insider selling, though the pre-arranged 10b5-1 plan typically mitigates significant concern. The transaction itself does not impact the company's operational performance or financial health.

Key Dates

Recommendation

This Form 4 filing details a routine, pre-scheduled insider transaction (exercise of options and sale of shares under a 10b5-1 plan). It does not provide new information regarding the company's operational performance, strategic direction, or financial health that would warrant a change in investment recommendation. The transaction reflects a personal liquidity event for the executive rather than a signal about the company's future prospects.

Keywords

United Therapeutics, UTHR, Form 4, insider trading, stock options, 10b5-1 plan, executive compensation, Paul A. Mahon, share sale